Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 8/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10100786 | 0.96 | EPHX2 (0.42) | EPHX2CHEK2CYP2A6KDRFLT1 | |
| SCHEMBL10100606 | 0.85 | CHEK1 (0.38) | CHEK2CHEK1TLR7FYNNTRK1 | |
| SCHEMBL10100607 | 0.84 | GRIN2B (0.36) | CHEK2TLR7FYNNTRK1 | |
| SCHEMBL10100602 | 0.83 | LRRK2 (0.41) | KDR | |
| SCHEMBL10100590 | 0.83 | EPHX2 (0.43) | EPHX2CHEK2CYP2A6KDRFLT1 | |
| SCHEMBL10100775 | 0.82 | EPHX2 (0.42) | EPHX2CHEK2CYP2A6KDRFLT1 | |
| SCHEMBL10100603 | 0.82 | LRRK2 (0.45) | TLR7 | |
| SCHEMBL10100619 | 0.81 | MAPK1 (0.39) | — | |
| SCHEMBL10100535 | 0.80 | EPHX2 (0.42) | EPHX2CHEK2CYP2A6KDRFLT1 | |
| SCHEMBL10100785 | 0.80 | LRRK2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2010048131-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | EPHX2 2778/4885CHEK2 109/4885CYP2A6 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.